Chemical Proteomics Identifies Nampt as the Target of CB30865, An Orphan Cytotoxic Compound

Chemistry and Biology

Volumn 17, Issue 6, 2010, Pages 659-664

  Fleischer, Tracey C ^a   Murphy, Brett R ^a   Flick, Jeffrey S ^a   Terry Lorenzo, Ryan T ^a   Gao, Zhong Hua ^a   Davis, Thaylon ^a   McKinnon, Rena ^a   Ostanin, Kirill ^a   Willardsen, J Adam ^a   Boniface, J Jay ^a  

^a Myriad Pharmaceuticals   (United States)

Author keywords

CHEMBIO

Indexed keywords

4 [N (7 BROMO 3,4 DIHYDRO 2 METHYL 4 OXO 6 QUINAZOLINYLMETHYL) N (2 PROPYNYL)AMINO] N (3 PYRIDYLMETHYL)BENZAMIDE; ANTINEOPLASTIC AGENT; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; QUINAZOLINE DERIVATIVE; CB 30865;

ARTICLE; CELL STRAIN HCT116; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG MANUFACTURE; HUMAN; METABOLISM; METHODOLOGY; PROTEOMICS; ANTAGONISTS AND INHIBITORS; HCT116 CELL LINE; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HCT116 CELLS; HUMANS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ORPHAN DRUG PRODUCTION; PROTEOMICS; QUINAZOLINES;

EID: 77953696907     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.05.008     Document Type: Article

References (21)

1. Bavetsias V., Skelton L.A., Yafai F., Mitchell F., Wilson S.C., Allan B., and Jackman A.L. The design and synthesis of water-soluble analogues of CB30865, a quinazolin-4-one-based antitumor agent. J. Med. Chem. 45 (2002) 3692-3702
2. Borradaile N.M., and Pickering J.G. NAD(+), sirtuins, and cardiovascular disease. Curr. Pharm. Des. 15 (2009) 110-117
3. Eng J., McCormack A., and Yates J.R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5 (1994) 976-989
4. Gallí M., Van Gool F., Rongvaux A., Andris F., and Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 70 (2010) 8-11
5. Holen K., Saltz L.B., Hollywood E., Burk K., and Hanauske A.R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs 26 (2008) 45-51
6. Hovstadius P., Larsson R., Jonsson E., Skov T., Kissmeyer A.M., Krasilnikoff K., Bergh J., Karlsson M.O., Lönnebo A., and Ahlgren J. A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin. Cancer Res. 8 (2002) 2843-2850
7. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr. Pharm. Des. 15 (2009) 20-28
8. Jones T.R., Calvert A.H., Jackman A.L., Eakin M.A., Smithers M.J., Betteridge R.F., Newell D.R., Hayter A.J., Stocker A., Harland S.J., et al. Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituent. J. Med. Chem. 28 (1985) 1468-1476
9. Kang G.B., Bae M.H., Kim M.K., Im I., Kim Y.C., and Eom S.H. Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor. Mol. Cells 27 (2009) 667-671
10. Khan J.A., Tao X., and Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol. 13 (2006) 582-588
11. Lu Y.J., Williamson D., Clark J., Wang R., Tiffin N., Skelton L., Gordon T., Williams R., Allan B., Jackman A., et al. Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. Proc. Natl. Acad. Sci. USA 98 (2001) 9197-9202
12. Martin P.R., Shea R.J., and Mulks M.H. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J. Bacteriol. 183 (2001) 1168-1174
13. McAfee K.J., Duncan D.T., Assink M., and Link A.J. Analyzing proteomes and protein function using graphical comparative analysis of tandem mass spectrometry results. Mol. Cell. Proteomics 5 (2006) 1497-1513
14. Preiss J., and Handler P. Enzymatic synthesis of nicotinamide mononucleotide. J. Biol. Chem. 225 (1957) 759-770
15. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., and Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32 (2002) 3225-3234
16. Ravaud A., Cerny T., Terret C., Wanders J., Bui B.N., Hess D., Droz J.P., Fumoleau P., and Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumors: an ECSG/EORTC study. Eur. J. Cancer 41 (2005) 702-707
17. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14 (1994) 1431-1437
18. Skelton L.A., Ormerod M.G., Titley J.C., and Jackman A.L. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry 33 (1998) 56-66
19. Skelton L.A., Ormerod M.G., Titley J., Kimbell R., Brunton L.A., and Jackman A.L. A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus. Br. J. Cancer 79 (1999) 1692-1701
20. von Heideman A., Berglund A., Larsson R., and Nygren P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol. 65 (2009) 1165-1172
21. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol. 29 (2009) 5872-5888